Study of the Safety of Intravenous Artesunate

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 12, 2006

Primary Completion Date

January 17, 2007

Study Completion Date

January 31, 2008

Conditions
MalariaMalaria, Cerebral
Interventions
DRUG

Intravenous Artesunate

Three doses of Intravenous Artesunate drug at 2, 4, or 8 mg/kg in diluent Phosphate Buffer (0.3 M, pH 8.1)

DRUG

Placebo

Mannitol (200 mg/vial) diluted in Phosphate Buffer and given IV in equivalent volume by subject's weight.

Trial Locations (1)

20814-4799

Uniformed Services University of the HEalth Sciences, Bethesda

All Listed Sponsors
collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

lead

U.S. Army Medical Research and Development Command

FED

NCT00292942 - Study of the Safety of Intravenous Artesunate | Biotech Hunter | Biotech Hunter